首页> 美国卫生研究院文献>Cancers >Palliative Interventional and Surgical Therapy for Unresectable Pancreatic Cancer
【2h】

Palliative Interventional and Surgical Therapy for Unresectable Pancreatic Cancer

机译:不能切除的胰腺癌的姑息介入治疗和手术治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Palliative treatment concepts are considered in patients with non-curatively resectable and/or metastasized pancreatic cancer. However, patients without metastases, but presented with marginally resectable or locally non-resectable tumors should not be treated by a palliative therapeutic approach. These patients should be enrolled in neoadjuvant radiochemotherapy trials because a potentially curative resection can be achieved in approximately one-third of them after finishing treatment and restaging. Within the scope of best possible palliative care, resection of the primary cancer together with excision of metastases represents a therapeutic option to be contemplated in selected cases. Comprehensive palliative therapy is based on treatment of bile duct or duodenal obstruction for certain locally unresectable or metastasized advanced pancreatic cancer. However, endoscopic or percutaneous stenting procedures and surgical bypass provide safe and highly effective therapeutic alternatives. In case of operative drainage of the biliary tract (biliodigestive anastomosis), the prophylactic creation of a gastro-intestinal bypass (double bypass) is recommended. The decision to perform a surgical versus an endoscopic procedure for palliation depends to a great extent on the tumor stage and the estimated prognosis, and should be determined by an interdisciplinary team for each patient individually.
机译:患有非治愈性可切除和/或转移性胰腺癌的患者应考虑姑息治疗方案。但是,无转移但出现可切除或局部不可切除的肿瘤的患者,不应采用姑息治疗方法进行治疗。这些患者应参加新辅助放化疗试验,因为在完成治疗和分期后,大约有三分之一的患者可能获得治愈性切除。在最佳的姑息治疗范围内,切除原发癌并切除转移灶是某些病例的治疗选择。全面的姑息治疗基于对某些局部不可切除或转移的晚期胰腺癌的胆管或十二指肠梗阻的治疗。但是,内窥镜或经皮支架置入程序和手术旁路提供了安全有效的治疗选择。如果胆道手术引流(胆消化道吻合术),建议预防性使用胃肠道旁路(双旁路)。手术还是内窥镜下手术以减轻疼痛的决定在很大程度上取决于肿瘤的分期和估计的预后,并应由跨学科团队针对每个患者分别确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号